Drugs / NF-kappaB Decoy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00125333 | Mar → Nov 2005 | atopic eczema | Anesiva, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NF-kappaB Decoy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00125333 ↗ |
| Action | Inhibit | “thereby inhibiting the production of the inflammatory response triggered by NF-kappaB” NCT00125333 ↗ |
| Modality | Oligonucleotide (other) | “double-stranded deoxyribonucleic acid (DNA) oligodeoxynucleotide” NCT00125333 ↗ |
| Route | Topical | “repeated topical application of three concentrations of NF-kappaB Decoy” NCT00125333 ↗ |